Evidence map›Paper›PMID 37480482›Full record

ArticleInternational urology and nephrology2024

Colquhounia root tablet in the treatment of idiopathic membranous nephropathy with subnephrotic proteinuria.

Chunyan Xu, Tianhua Xu, Nan Liu, Linlin Liu, Li Sun, Xiaoli Li, Zilong Li, Li Yao

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chunyan XuThe First Hospital of China Medical University, 155 Nanjing Street, Heping District, Shenyang, 110002, China.
Tianhua XuThe First Hospital of China Medical University, 155 Nanjing Street, Heping District, Shenyang, 110002, China.
Nan LiuThe First Hospital of China Medical University, 155 Nanjing Street, Heping District, Shenyang, 110002, China.
Linlin LiuThe First Hospital of China Medical University, 155 Nanjing Street, Heping District, Shenyang, 110002, China.
Li SunThe First Hospital of China Medical University, 155 Nanjing Street, Heping District, Shenyang, 110002, China.
Xiaoli LiThe First Hospital of China Medical University, 155 Nanjing Street, Heping District, Shenyang, 110002, China.
Zilong LiThe First Hospital of China Medical University, 155 Nanjing Street, Heping District, Shenyang, 110002, China.
Li YaoThe First Hospital of China Medical University, 155 Nanjing Street, Heping District, Shenyang, 110002, China. liyao_cmu@163.com.

Funding

the National Natural Science Foundation of China 82070763the Nature Science Foundation of Liaoning Province 2020JH2/10300045
6 · The paper itself

Abstract

purposeIdiopathic membranous nephropathy (IMN) is the most frequent global cause of nephrotic syndrome in non-diabetic people. In clinical practice, An effective and mild treatment for IMN patients with subnephrotic proteinuria has been adopted. Colquhounia root tablet (CRT) is a traditional Chinese medicine that is widely used in China to treat glomerulopathies. In this study, the effectiveness and safety of CRT in the treatment of IMN with subnephrotic proteinuria have been determined by reviewing the clinical records of 44 patients with IMN.

methodsRetrospective analysis of IMN patients with subnephrotic proteinuria treated with CRT in combination with ACEI/ARB or ACEI/ARB alone. The remission rate (complete or partial remission) was the main outcome observed, and proteinuria, estimated glomerular filtration rate (eGFR), serum albumin levels, and adverse effects were the secondary outcomes.

resultsThis clinical trial included 44 patients, and the overall remission rates at months 6, 9, and 12 after treatment were 68.2% versus 27.3% (p = 0.016), 72.7% versus 36.4% (p = 0.015), and 77.3% versus 36.4% (p = 0.006) in the treatment and control groups, respectively. The application of CRT treatment was an independent predictor of proteinuria remission (p = 0.024). In addition, in patients who were positive for phospholipase A2 receptor (PLA2R) antibodies, the overall remission rate was higher in the treatment group than in the control group after 9 months of treatment (75% versus 23.08%, p = 0.017).

conclusionThis retrospective study illustrates that, based on supportive therapy, CRT could be effective in the treatment of IMN with subnephrotic proteinuria with a good safety profile at the same time.

Indexed as

Angiotensin Receptor AntagonistsGlomerulonephritis, MembranousAngiotensin-Converting Enzyme InhibitorsHumansProteinuriaRetrospective StudiesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAnti-phospholipase A2 receptorColquhounia root tabletMembranous nephropathySubnephrotic proteinuria

Identifiers

PMID37480482

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.